ArticleTranslational breast cancer research : a journal focusing on translational research in breast cancer2026

Eligibility for adjuvant CDK4/6 inhibitors in HR+/HER2- early breast cancer: insights from a large cohort in central south China.

Jianmin Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.